Ratings SynBiotic SE

Equities

End-of-day quote BOERSE DUESSELDORF Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.5 ^EUR	+4.17%		-6.40%	+217.73%

Apr. 23	SynBiotic Boosts CBD Business with Ilesol Pharmaceuticals Takeover	MT
Apr. 23	SynBiotic SE acquired Ilesol Pharmaceuticals d.o.o. za proizvodnju i usluge.	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SYNBIOTIC SE	+217.73%	47.64M		-
CURALEAF HOLDINGS, INC.	+56.08%	3.73B		C-
TRULIEVE CANNABIS CORP.	+188.32%	2.03B		C
GOODNESS GROWTH HOLDINGS, INC.	+144.44%	59.76M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality